Frankis Jamie, Flowers Paul, McDaid Lisa, Bourne Adam
School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, G4 0BA, UK.
MRC/CSO Social & Public Health Sciences Unit, University of Glasgow, Glasgow, G12 8QQ, UK.
Sex Health. 2018 Apr;15(2):144-150. doi: 10.1071/SH17159.
Background This paper establishes the prevalence of chemsex drug use among men who have sex with men (MSM), the extent to which these drugs are used in a sexual context, as well as their associated behaviours and circumstances of use.
Data from a cross-sectional, online survey of 2328 MSM recruited via gay sociosexual media in Scotland, Wales, Northern Ireland and the Republic of Ireland were analysed.
While almost half (48.8%) of participants had ever taken illicit drugs, lifetime chemsex drug use was less common (18.0%) and far fewer reported chemsex drug use in the last year (8.2%) or last 4 weeks (3.0%). Just over one-quarter (27.1%) of men who used chemsex drugs in the last year reported no sexualised drug use, but almost three-quarters (72.9%) did. Only 6.1% of the whole sample reported sexualised chemsex drug use in the last year. The odds of reporting chemsex in the last year were significantly higher for men aged 36-45 years (AOR=1.96), single men (AOR=1.83), men who were HIV positive (AOR=4.01), men who report high-risk sex (AOR=4.46), being fisted (AOR=7.77) or had sex in exchange for goods other than money (AOR=4.7) in the last year and men who reported an HIV test in the last 3 months (AOR=1.53).
Only a small proportion of MSM in Scotland, Wales, Northern Ireland and the Republic of Ireland reported chemsex, and, for the first time, it is demonstrated that not all chemsex drug use was sexualised. Nevertheless, MSM who engage in chemsex (MWEC) reported substantial sexual risk inequalities. These novel findings highlight several opportunities for intervention, particularly around the multiple vulnerabilities of MWEC, opportunities for early identification of those most vulnerable to chemsex-related harm and the potential to develop a specialised responsive patient pathway.
背景 本文确定了男男性行为者(MSM)中使用催情药的流行情况、这些药物在性情境中的使用程度,以及其相关行为和使用情况。
对通过苏格兰、威尔士、北爱尔兰和爱尔兰共和国的同性恋社交性媒体招募的2328名男男性行为者进行的横断面在线调查数据进行了分析。
虽然近一半(48.8%)的参与者曾使用过非法药物,但终身使用催情药的情况较少见(18.0%),去年报告使用催情药的人数更少(8.2%),过去4周内使用催情药的人数为3.0%。去年使用催情药的男性中,略多于四分之一(27.1%)报告没有在性行为中使用药物,但近四分之三(72.9%)的人有过。去年整个样本中只有6.1%的人报告在性行为中使用催情药。36至45岁的男性(调整后比值比[AOR]=1.96)、单身男性(AOR=1.83)、艾滋病毒呈阳性的男性(AOR=4.01)、报告有高危性行为的男性(AOR=4.46)、去年有过被拳交经历的男性(AOR=7.77)或有过以物易性经历的男性(AOR=4.7)以及过去3个月内报告进行过艾滋病毒检测的男性(AOR=1.53),去年报告使用催情药的几率显著更高。
在苏格兰、威尔士、北爱尔兰和爱尔兰共和国,只有一小部分男男性行为者报告使用催情药,并且首次证明并非所有催情药的使用都是在性行为中。然而,从事催情药使用的男男性行为者(MWEC)报告了严重的性风险不平等。这些新发现凸显了几个干预机会,特别是围绕MWEC的多重脆弱性、早期识别最易受催情药相关伤害者的机会以及开发专门应对患者途径的潜力。